ASCLF (Ascletis Pharma) Moat Score: 4/10 (As of Jul. 13, 2026)


ASCLF Ascletis Pharma Inc ASCLF
38 GF Score
Price $1.44
GF Value $0.02
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ascletis Pharma Moat Score?

Ascletis Pharma ASCLF -4.00% 38 Moat Score is 4 as of Jul. 13, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,396 Biotechnology companies, Ascletis Pharma ranks better than 88.75% on this metric.

Ascletis Pharma has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Ascletis Pharma has Narrow Moat: Ascletis Pharma has a discernible but modest moat due to its valuable intellectual property and patents in the pharmaceutical sector. However, it lacks strong brand strength and significant customer switching costs, limiting its competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ascletis Pharma might have Narrow Moat - Discernible but modest moat.

Ascletis Pharma  (OTCPK:ASCLF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ascletis Pharma Moat Score Related Terms

ASCLF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Ascletis Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Moat Score falls into.


ASCLF
38GF Score
Ascletis Pharma Inc ASCLF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Ascletis Pharma (ASCLF) has a Moat Score of 4 as of Jul. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ascletis Pharma ranks #157 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Ascletis Pharma's Moat Score too high?
Ascletis Pharma's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Ascletis Pharma's value of 4 is 100% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #157 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #157 out of 1396 companies for Moat Score. This places Ascletis Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Ascletis Pharma's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Moat Score is 4 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascletis Pharma (ASCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for ASCLF:

  • Moat Score: 4
  • GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
  • GF Score™: 38/100 with 5 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1396)

No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascletis Pharma Business Description

Other Exchanges 01672:Hong Kong2VJ:Germany
Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score

Get the complete analysis for ASCLF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.02
GF Value